UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 23.

Jentzmik, F; Stephan, C; Lein, M; Miller, K; Kamlage, B; Bethan, B; Kristiansen, G; Jung, K (2011). Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. The Journal of Urology, 185(2):706-711.

Gerhardt, J; Steinbrech, C; Büchi, O; Behnke, S; Bohnert, A; Fritzsche, F; Liewen, H; Stenner, F; Wild, P; Hermanns, T; Müntener, M; Dietel, M; Jung, K; Stephan, C; Kristiansen, G (2011). The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro. American Journal of Pathology, 178(4):1847-1860.

Schaefer, A; Jung, M; Kristiansen, G; Lein, M; Schrader, M; Miller, K; Stephan, C; Jung, K (2010). MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urologic Oncology, 28(1):4-13.

Aguilar, C; Carlier, A; Riedel, K; Eberl, L (2010). Cell-cell communication in biofilms of gram-negative bacteria. In: Krämer, R; Jung, K. Bacterial signaling. Weinheim, DE: Wiley-VCH, 23-40.

Tischler, V; Fritzsche, F R; Wild, P J; Stephan, C; Seifert, H H; Riener, M O; Hermanns, T; Mortezavi, A; Gerhardt, J; Schraml, P; Jung, K; Moch, H; Soltermann, A; Kristiansen, G (2010). Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer, 10:273.

Schaefer, A; Jung, M; Miller, K; Lein, M; Kristiansen, G; Erbersdobler, A; Jung, K (2010). Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Experimental and Molecular Medicine, 42(11):749-758.

Knösel, M; Jung, K; Attin, T; Attin, R; Kubein-Meesenburg, D; Gripp-Rudolph, L (2009). Systematic evaluation of the features influencing the accuracy of third order measurements. European Journal of Orthodontics, 31(5):547-555.

Knösel, M; Jung, K; Gripp-Rudolph, L; Attin, T; Attin, R; Sadat-Khonsari, R; Kubein-Meesenburg, D; Bauss, O (2009). Changes in incisor third-order inclination resulting from vertical variation in lingual bracket placement. Angle Orthodontist, 79(4):747-754.

Knösel, M; Jung, K; Attin, T; Engelke, W; Kubein-Meesenburg, D; Gripp-Rudolph, L; Attin, R (2009). On the interaction between incisor crown-root morphology and third-order angulation. Angle Orthodontist, 79(3):454-461.

Knösel, M; Attin, R; Jung, K; Brunner, E; Kubein-Meesenburg, D; Attin, T (2009). Digital image color analysis compared to direct CIE colorimeter assessment under different ambient conditions. American Journal of Dentistry, 22(2):67-72.

Meyer, H A; Tölle, A; Jung, M; Fritzsche, F R; Haendler, B; Kristiansen, I; Gaspert, A; Johannsen, M; Jung, K; Kristiansen, G (2009). Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. European Urology, 55(3):669-678.

Gutwein, P; Schramme, A; Sinke, N; Abdel-Bakky, M S; Voss, B; Obermüller, N; Doberstein, K; Koziolek, M; Fritzsche, F; Johannsen, M; Jung, K; Schaider, H; Altevogt, P; Ludwig, A; Pfeilschifter, J; Kristiansen, G (2009). Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. European Journal of Cancer, 45(3):478-489.

Tölle, A; Jung, M; Lein, M; Johannsen, M; Miller, K; Moch, H; Jung, K; Kristiansen, G (2009). Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? BMC Cancer, 9:248.

Kataru, R P; Jung, K; Jang, C; Yang, H; Schwendener, R; Baik, J E; Han, S H; Alitalo, K; Koh, G Y (2009). Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood, 113(22):5650-5659.

Kempkensteffen, C; Fritzsche, F R; Johannsen, M; Weikert, S; Hinz, S; Dietel, M; Riener, M O; Moch, H; Jung, K; Krause, H; Miller, K; Kristiansen, G (2009). Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. BMC Cancer, 9:276.

Schaefer, A; Jung, M; Kristiansen, G; Lein, M; Schrader, M; Miller, K; Erbersdobler, A; Stephan, C; Jung, K (2009). Mikro-RNA in der Uroonkologie. Neue Hoffnungen für die Diagnostik und Therapie von Tumoren? Der Urologe. Ausg. A, 48(8):877-885.

Fritzsche, F R; Jung, M; Tölle, A; Wild, P; Hartmann, A; Wassermann, K; Rabien, A; Lein, M; Dietel, M; Pilarsky, C; Calvano, D; Grützmann, R; Jung, K; Kristiansen, G (2008). ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. European Urology, 54(5):1097-1108.

Fritzsche, F R; Wassermann, K; Jung, M; Tölle, A; Kristiansen, I; Lein, M; Johannsen, M; Dietel, M; Jung, K; Kristiansen, G (2008). ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer, 8:179.

Fritzsche, F R; Oelrich, B; Johannsen, M; Kristiansen, I; Moch, H; Jung, K; Kristiansen, G (2008). Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clinical Cancer Research, 14(21):7035-7042.

Fritzsche, F R; Riener, M O; Dietel, M; Moch, H; Jung, K; Kristiansen, G (2008). GOLPH2 expression in renal cell cancer. BMC Urology, 8:15.

Kristiansen, G; Fritzsche, F R; Wassermann, K; Jäger, C; Tölle, A; Lein, M; Stephan, C; Jung, K; Pilarsky, C; Dietel, M; Moch, H (2008). GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. British Journal of Cancer, 99(6):939-948.

Weichert, W; Röske, A; Gekeler, V; Beckers, T; Stephan, C; Jung, K; Fritzsche, F R; Niesporek, S; Denkert, C; Dietel, M; Kristiansen, G (2008). Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. British Journal of Cancer, 98(3):604-610.

Jeon, B H; Jang, C; Han, J; Kataru, R P; Piao, L; Jung, K; Cha, H J; Schwendener, R; Jang, K Y; Kim, K S; Alitalo, K; Koh, G Y (2008). Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Research, 68(4):1100-9.

This list was generated on Thu Jul 20 17:16:03 2017 CEST.